| Name | Title | Contact Details |
|---|
Since our first facility opened in 1970, Life Care`s associates have positively impacted the company`s mission of providing exceptional patient care. Life Care owns or manages more than 200 facilities and employs approximately 40,000 individuals who strive daily to make a difference in the lives of those we serve. Our facilities offer multiple levels of patient care and services, which vary by location. We offer post-acute care and inpatient and outpatient therapy in well-equipped, on-site rehabilitation gyms. We believe that as a privately owned company, Life Care Centers of America stands apart from others. We offer a resident-centered corporate culture with more than 45 years of experience, stability and success. Our modern and well-maintained facilities feature strong multidisciplinary teams, specialty programs and opportunities for continuing education.
Clark Regional Medical Center is committed to providing the medical and surgical needs of our community. Our state-of-the-art equipment and services, combined with our experienced medical staff provides the best possible care in our region. Our Board
Caring Companions is a Youngwood, PA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Marathon Health is based in Indianapolis, IN and Winooski, VT. When we say we are a different kind of healthcare company, we mean we`re a better kind. What makes us better is that we guide people to take control of their own health. We operate on a simple premise: when people are given the tools they need to manage their own health and healthcare, the cost of healthcare is lower. We believe the best way to keep people healthy is to help them manage risk factors and chronic conditions, and to keep them from getting sick in the first place. To do this, we combine a powerful collection of onsite health services into a program tailored to your unique culture, setting, and workforce.
Immune Pharmaceuticals applies a personalized approach to treatment, developing novel, highly targeted antibody therapeutics to improve the lives of patients with inflammatory diseases and cancer. The Company’s lead product candidate, bertilimumab, is entering Phase II clinical studies for moderate-to-severe ulcerative colitis and bullous pemphigoid, with additional studies planned for Crohn’s disease and severe asthma. The Company is evaluating the use of its NanomAb® platform, a second generation antibody drug conjugate technology, with chemotherapeutics in order to enhance their safety and efficacy profiles by delivering the medicines directly to cancer cells. The Company’s growing oncology pipeline also includes proprietary antibodies and, clinical-stage small molecules that have been shown activity in a variety of solid tumors. Immune is headquartered in the U.S., with its primary research and development facilities in Israel.